Your search for ‘Wilson Sonsini Goodrich & Rosati’ returned 69 results

The Prescription Drug User Fee Act of 2017 (PDUFA VI) authorizes the U.S. Food and Drug Administration (FDA) to assess fees (PDUFA fees) when applicants submit new drug applications (NDAs).

With the close of the California legislative session on September 13, 2019, the final amendments to the California Consumer Protection Act ("CCPA") have been submitted to California Governor...

The past few years have seen a rise in heads of innovation at Big Law firms. One of the leading voices in this space is David Wang, Wilson Sonsini Goodrich & Rosati's chief innovation officer.

In 2018, the administration published its Blueprint to Lower Drug Prices for U.S. citizens.

On October 5, 2009, the Federal Trade Commission (FTC) published its revised Guides Concerning Use of Endorsements and Testimonials in Advertising.

The 2nd Annual Microbiome Movement conference, recently held in San Diego, California, highlighted the growing importance of microbes as the basis for various commercial products.

Senator Charles Grassley (R-IA), chairman of the Senate Finance Committee, sent a letter in August to Novartis International AG CEO Vasant Narasimhan requesting documents relating to...

On October 9, 2019, the U.S. Department of Health and Human Services' (HHS') Centers for Medicare and Medicaid Services (CMS) and Office of Inspector General...

The past few years have seen a rise in heads of innovation at Big Law firms. One of the leading voices in this space is David Wang, Wilson Sonsini Goodrich & Rosati's chief innovation officer.

The CFPB regulates entities that provide consumer financial products or services.

Until September 30, 2019, Securities and Exchange Commission ("SEC") enforcement actions in the crypto industry conveyed a consistent message: most crypto is a security